Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M Falques
PTU-152 Significant Improvements in Abdominal Pain and Bowel Symptoms in a Phase 3 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): A European Perspective
Gut
Gastroenterology
Related publications
PWE-026 Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): Abstract PWE-026 Table
Gut
Gastroenterology
Clinical Response to Linaclotide at Week 4 Predicts Sustained Response in Irritable Bowel Syndrome With Constipation and Improvements in Digestive and Extra-Digestive Symptoms
Therapeutic Advances in Gastroenterology
Gastroenterology
Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation in Adults
Clinical Medicine Insights: Gastroenterology
Gastroenterology
Review: Soluble Fibre Improves Overall Symptoms and Constipation but Not Abdominal Pain in Irritable Bowel Syndrome
Evidence-Based Medicine
Medicine
PWE-167 Effect of Linaclotide on Ibs-Qol Sexual Subscale Scores in Patients With Irritable Bowel Syndrome With Constipation: Results From 2 Phase 3 Trials: Abstract PWE-167 Table 1
Gut
Gastroenterology
Abdominal Bloating Is the Most Bothersome Symptom in Irritable Bowel Syndrome With Constipation (IBS-C): A Large Population-Based Internet Survey in Japan
BioPsychoSocial Medicine
Psychiatry
Social Psychology
Mental Health
Psychology
Biological Psychiatry
Lovastatin Lactone May Improve Irritable Bowel Syndrome With Constipation (IBS-C) by Inhibiting Enzymes in the Archaeal Methanogenesis Pathway
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Faecal Biomarker Patterns in Patients With Symptoms of Irritable Bowel Syndrome
Frontline Gastroenterology
Hepatology
Gastroenterology
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
American Journal of Gastroenterology
Hepatology
Gastroenterology
